Rosiglitazone suppresses angiogenesis in multiple myeloma via downregulation of hypoxia‑inducible factor‑1α and insulin‑like growth factor‑1 mRNA expression

Introduction

Multiple myeloma (MM) is an incurable plasma cell neoplasm; however, patient survival rates have improved in the last decade due to the introduction of several effective therapies, including thalidomide and bortezomib (1). These drugs are expensive and the wide clinical application is limited in China, thus the development of new drugs is important for the treatment of multiple myeloma. Bone marrow (BM) angiogenesis exhibits an important role in the pathogenesis and progression of MM (2). Inducers of angiogenesis in the BM microenvironment include insulin-like growth factor-1 (IGF-1), vascular endothelial growth factor (VEGF), and hypoxia-inducible transcription factor-1 (HIF-1) (3). Thus far, angiogenesis is the best-documented biological consequence of aberrant HIF expression in MM. Studies have shown that there is a positive correlation between HIF-1α expression and the levels of BM angiogenesis, and expression of VEGF and VEGF receptor in biopsy specimens of patients with MM (4). Overexpression of HIF-1 in MM cells significantly enhanced MM-induced angiogenesis in an in vivo xenograft model (5). Small interfering RNA-mediated knockdown of HIF-1α expression in RPMI-8226 cells and CD138-positive MM cells significantly reduced MM-induced angiogenesis in vitro (6). HIF-1 activation promotes the aberrant production of VEGF by MM and angiogenesis, and is associated with a poor prognosis in patients with MM (7). IGF-1 has been shown to activate VEGF expression in MM (8). IGF-1 is a cytokine that exhibits a role in MM development and promotes angiogenesis (9). The serum levels of IGF-1 in patients with newly diagnosed MM are positively correlated with markers of angiogenesis, including VEGF (10).

Several studies have provided evidence that the levels of nuclear translocation of HIF-1α are increased following stimulation with IGF-1 (11–13). IGF1 has been shown to promote VEGF secretion in the 5T33MM model via the mitogen-activated protein kinase kinase/extracellular signal-regulated kinase (ERK) signaling pathway, independent of phosphatidylinositol 3-kinase (PI3K) (14). IGF-1 has been shown to upregulate the levels of VEGF production via HIF-1α in an AKT-dependent manner (15). A study has reported that the regulatory mechanism of HIF-1 activation is closely associated with ERK (16). HIF-1α is phosphorylated in hypoxia via an ERK-dependent signaling pathway (17). HIF-1 is activated by increased levels of VEGF production and transactivation via the PI3K/AKT and mitogen-activated protein kinase kinase/ERK signaling pathways in breast cancer (18).

A previous study confirmed that rosiglitazone (RGZ), a thiazolidinedione ligand of the peroxisome proliferator-activated receptor-γ, can inhibit myeloma cell proliferation, cell cycle arrest, apoptosis and differentiation (19). The expression levels of IGF1-mRNA have been found to be reduced following RGZ treatment and the levels of IGF-1 secretion were suppressed (20). Treatment with RGZ can attenuate the activation and expression of HIF-1 (21). The present study demonstrated that RGZ reduces the expression of HIF-1α and IGF1 mRNA in RPMI-8226 and primary myeloma cells from patients. In addition, the molecular mechanisms underlying its anti-angiogenic effects was investigated.

Materials and methods

Cell lines and reagents

The RPMI-8226 myeloma cell line was provided by Professor Xueguang Zhang (Institute of Biological Technology, Soochow University, China). Cells were maintained in RPMI-1640 supplemented with 10% fetal calf serum, 2 mM glutamine and 1% penicillin/streptomycin (Gibco-BRL, Grand Island, NY, USA). Cells were cultured at 37°C in a humidified 5% CO2 atmosphere and passaged every 2–3 days. RGZ was purchased and dissolved in dimethylsulfoxide (DMSO; Sigma-Aldrich, St. Louis, MO, USA). Anti-mouse phospho-AKT monoclonal antibody and anti-mouse phospho-ERK ½ monoclonal antibody were purchased from Cell Signaling Technology, Inc. (Danvers, MA, USA) and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was purchased from Abcam (Cambridge, UK).

Cell viability assay

The viability of the cells was assessed by an MTT assay. Cells (2x104 cells/well) were seeded in a 96-well plate and treated with the vehicle control (<0.1% DMSO) or RGZ at various concentrations (10, 20 or 40 μM). For the time course experiment, cells were incubated for 24, 48 or 72 h. A solution of 20 μl/well (MTT, 5 mg/ml; Sigma, St. Louis, MO, USA) was added to each well for the last 4 h of incubation. After 4 h, the plate was centrifuged at 1,000 rpm for 10 min the media removed and 150 μl DMSO was added to each well to dissolve the precipitate. The plate was then read at 570 nm in an ELISA microplate reader (ELX800; Bio-Rad, Hercules, CA, USA). Five replicate wells were used for each analysis. A percentage of the viability of the controls was presented in culture conditions.

Isolation of BM cells from the patients

This study was approved by the Ethics Committee of the Second Affiliated Hospital of Soochow University and informed consent was obtained from all patients in accordance with the Declaration of Helsinki protocol. Mononuclear cells were freshly isolated from the BM of five patients with MM and five healthy patients by Ficoll-Hypaque density gradient centrifugation (Sigma). Myeloma cells were purified with the CD138 positive selection method using CD138 immunomagnetic beads and a magnetic cell sorter (AutoMACS; Miltenyi Biotec Ltd., Surrey, UK), according to the manufacturer’s instructions. The primary CD138-positive myeloma cells were viable (95–97%) in vitro. The cell density was maintained at 5×105 cells/ml and cells were treated with RGZ at various concentrations (10, 20 or 40 μM) for 48 h.

RNA extraction and reverse transcription-polymerase chain reaction

Total RNA was obtained from the cultured cells using TRIzol (Takara Bio, Inc., Shiga, Japan). Total RNA (1 μg) was used for reverse transcription, which was performed with reverse transcriptase from Invitrogen Life Technologies (Carlsbad, CA, USA) at 65°C for 5 min, 42°C for 60 min and 70°C for 15 min. Amplification started with a 5 min denaturation step at 95°C, followed by 35 cycles of denaturation at 95°C for 15 sec and annealing at 60°C for 45 sec for HIF1α, or 35 cycles of denaturation at 95°C for 30 sec and annealing at 55°C for 45 sec for IGF1 and GAPDH. The sequences of the oligonucleotides used as specific primers for each gene were as follows: Forward: 5′-ACAAGTCACAGGACAG3′ and reverse: 5′-AGGGAGAAAATCAAGTCG3′ for HIF1α; forward: 5′-AGCAGTCTTCCAACCCAATTA3′ and reverse: 5′-CACGGACAGAGCGAGCTG3′ for IGF1; and forward: 5′-GTGGTCTCCTCTGACTTCAAC-3′ and reverse: 5′-TCTCTTCCTCTTGTGCTCTTG-3′ for GAPDH.

Western blot analysis

RPMI-8226 cells (1×106) were seeded in six-well plates containing RPMI-1640 medium with 10% FBS and 1% antibiotics, and were then harvested 48 h after RGZ treatment. Following removal of the medium, the RPMI-8226 cells were washed twice with cold phosphate-buffered saline and lysed for 30 min in 100 μl ice-cold cell-lysis buffer containing proteinase inhibitors (1% cocktail and 1 mM phenylmethylsulfonyl fluoride). The protein concentration was determined using a bicinchoninic acid assay. Protein samples (50 μg) were denatured in 5× sodium dodecyl sulfate-polyacrylamide gel electrophoresis sample buffer and were subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis on 10% Tris-glycine gels. The separated proteins were transferred onto polyvinylidene fluoride membranes for 1 h at 80 V using a Mini Trans-Blot Electrophoretic Transfer Cell (Bio-Rad). The membranes were blocked with 5% non-fat milk at room temperature for 1 h. Anti-phospho-AKT (Cell Signaling Technology, Inc.), anti-phospho-ERK 1/2 (Cell Signaling Technology, Inc.) and GAPDH (Abcam; dilution ratio 1:1,000) were used to probe the protein levels of the different desired molecules at 4°C overnight. Further incubation with goat anti-mouse IgG peroxidase-conjugated secondary antibodies (Abcam) was conducted at room temperature for 2 h. Protein bands were detected using an Enhanced Chemiluminescence kit (Amersham Biosciences, Little Chalfont, UK).

Statistical analysis

Statistical analysis was performed with the Statistical Program for Social Sciences software, version 19.0 (IBM, Armonk, NY, USA). All data are expressed as the mean ± standard deviation. Analysis of variance was applied for comparison of the means of two or multiple groups, in which Student’s t-test was further used for the comparison of two groups. P<0.05 was considered to indicate a statistically significant difference.

Results

RGZ inhibits RPMI-8226 cell growth

To examine the effects of RGZ on myeloma cell growth, concentration- and time-response experiments were conducted. Cells were treated with RGZ at various concentrations dissolved in DMSO. After treatment with 10, 20 and 40 μmol/l RGZ for 48 h, the viability of RPMI-8226 cells was 40.8±1.5, 33.4±2.9 and 11.9±1.1%, respectively. After 24, 48 and 72 h treatment with 20 μM RGZ, the cell viability was 36.3±2.7, 33.4±2.9 and 14.3± 2.4%, respectively (Fig. 1). Higher levels of cell growth inhibition were observed at a RGZ concentration of 40 μM after 24, 48 and 72 h compared with those of the cells treated with 10 or 20 μM RGZ.

Figure 1 Rosiglitazone (RGZ) inhibited the growth of RPMI-8226 myeloma cells. Cells were treated with various concentrations of RGZ (0, 10, 20 and 40 μM) for different time periods. After 24, 48 and 72 h, cell viability was determined by an MTT assay. Results are representative of three experiments and each concentration was repeated five times in each experiment. Data are presented as the mean ± standard deviation. Significance was determined by Student’s t-test P<0.05, compared with control.

HIF1α and IGF1 mRNA are expressed in primary myeloma, RPMI-8226 and healthy donor cells

Mononuclear cells were freshly isolated from the BM of healthy patients, RPMI-8226 cells and primary myeloma cells by Ficoll-Hypaque density gradient centrifugation. The results demonstrated that a higher expression of HIF1α and IGF1 was detected in RPMI-8226 cells and primary myeloma cells compared with healthy donor cells (Fig. 2).

Figure 2 (A) mRNA expression levels of hypoxia-inducible transcription factor-1α (HIF1α) and insulin-like growth factor-1 (IGF1). Lane 1, RPMI-8226 cells; lane 2, primary myeloma cells; and lane 3, healthy donor cells (control). (B) The relative mRNA levels of HIF1α and IGF1. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as the internal control. Data are presented as the mean ± standard deviation. *P<0.05, vs. the control.

RGZ downregulates the expression of HIF1α and IGF1 mRNA in RPMI-8226 and primary myeloma cells

To determine whether HIF1α and IGF1 expression is affected in myeloma cells isolated from patients with MM and RPMI-8226 cells after 48 h incubation with RGZ, the expression levels of the corresponding mRNA were measured using reverse transcription-polymerase chain reaction amplification. The HIF1α and IGF1 gene expression levels were detected in the RPMI-8226 and primary myeloma cells. Following treatment with RGZ, the mRNA expression levels of HIF1α and IGF1 were concentration-dependently downregulated compared with those in the untreated cells (Fig. 3). GAPDH mRNA was used as the control.

Figure 3 Rosiglitazone (RGZ) induced the expression of hypoxia-inducible transcription factor-1α (HIF1α) and insulin-like growth factor-1 (IGF1). Cells were incubated with 0, 10, 20 and 40 μM of RGZ for 48 h. (A) RPMI-8226 cells and (B) primary myeloma cells were exposed to various concentrations of RGZ and the expression levels of HIF1α and IGF1 were estimated by reverse transcription-polymerase chain reaction. Relative mRNA levels of HIF1α and IGF1 in (C) RPMI-8226 cells and (D) primary myeloma cells. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as the internal control. Data are presented as the mean ± standard deviation. *P<0.05, vs. the control.

RGZ downregulates the functions of PI3K/AKT and ERK in RPMI-8226 cells

Based on the results shown in Fig. 4, RGZ was clearly able to inhibit pAKT and pERK expression after 48 h of treatment. When RPMI-8226 cells were cultured with various concentrations of RGZ for 48 h, the expression levels of pAKT and pERK in the RPMI-8226 cells gradually decreased in a concentration-dependent manner. In the RPMI-8226 cells treated for 48 h with 10 μM RGZ incubation, the protein expression levels of pAKT and pERK were relatively lower compared with those of the control. When the RGZ concentration was increased to 20 μM, the protein expression levels of pAKT and pERK were further reduced. At the RGZ concentration of 40 μM, the pAKT and pERK protein expression levels were significantly lower compared with those of the control.

Figure 4 Rosiglitazone (RGZ) treatment of RPMI-8226 cells reduced the levels of AKT and extracellular signal-regulated kinase (ERK) signaling. (A) Protein levels of pAKT and pERK. (B) Relative protein levels of pAKT and pERK. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as the internal control. Data are presented as the mean ± standard deviation. *P<0.05, vs. the control.

Discussion

A previous study confirmed that RGZ is able to induce cell cycle arrest, cell differentiation and apoptosis of MM cells (19). Numerous studies have shown that RGZ inhibits angiogenesis in various types of tumor, including human endometrial carcinoma (22), human ovarian cancer (23), lung cancer (24) and pancreatic carcinoma (25), and in other tissues, including in human umbilical vein endothelial cells (26). The present study assessed the inhibitory effects and molecular mechanisms of RGZ using RPMI-8226 myeloma cells and primary myeloma cells from patients. The MTT assay showed that RGZ inhibited the growth of RPMI-8226 cells in a time- and concentration-dependent manner. However, the optimal therapeutic strategy of targeting angiogenesis in MM with RGZ has not yet been identified. To the best of our knowledge, the present study reports for the first time, that RGZ has a potential antiangiogenic effect and may inhibit the PI3K/AKT and ERK signaling pathways in MM.

BM angiogenesis is important in the pathogenesis and progression of MM. The role of angiogenesis in growth, progression and metastatic spread of solid tumors has already been broadly confirmed (27). The progression of several cancers of hematopoietic lineages suggests a positive correlation between angiogenesis and progression, including that of non-Hodgkin’s lymphoma, lymphoblastic leukemia, B-cell chronic lymphocytic leukemia, acute myeloid leukemia and MM (28). A study has also shown that BM angiogenesis is a hallmark of MM progression (29). Tumor angiogenesis mainly depends on growth factors that are released by neoplastic cells and are able to stimulate the growth of the blood vessels of the host, particularly those of endothelial cells (30). An increasing number of studies have found that HIF1α and IGF1 exhibit a significant role in tumor angiogenesis. HIF1α promotes the formation of blood vessels in MM (7,4) and in other types of solid tumor, including bladder cancer (31), colon cancer (32) oral squamous cell carcinoma (33) and cervical carcinoma (34). IGF1 promotes angiogenesis in hepatocellular carcinoma (35) lung cancer (36) pancreatic ductal adenocarcinoma (37) and breast cancer (38).

In the present study, HIF1α and IGF1 mRNA expression levels were significantly increased in RPMI-8226 and primary myeloma cells compared with those in healthy donor cells. The results have confirmed the data of previous studies (3–5,10,39), which have suggested that high levels of HIF1α and IGF1 contribute to angiogenesis and promote MM disease progression.

Several studies have shown that RGZ-induced activation of peroxisome proliferator-activated receptor-γ inhibits angiogenesis in various types of tumor (22–25). Furthermore, it has been demonstrated that RGZ can suppress the levels of IGF-1 or HIF1α expression in vitro and in vivo (20,21). In the present study, when RPMI-8226 cells were incubated for 48 h with different concentrations of RGZ, the mRNA expression levels of HIF1α and IGF1 were downregulated in a concentration-dependent manner. In particular, when the concentration of RGZ increased to 40 μM, the mRNA expression levels of HIF1α and IGF1 were significantly reduced. Similar results were observed in CD138-positive myeloma cells from patients. These results suggest that when treated with RGZ, the expression levels of HIF1α and IGF1 decreased significantly in a concentration-dependent manner. These results indicated that RGZ may inhibit angiogenesis in a concentration-dependent manner in RPMI-8226 and primary myeloma cells through downregulation of the expression levels of HIF1α and IGF1.

A number of studies have suggested that the PI3K/AKT and ERK signaling pathways have an important role in angiogenesis (40–42). In a previous study, IGF-1 increased the expression levels of VEGF through the PI3K/AKT and ERK signaling pathways (14,43). Other studies have suggested that HIF1α promotes vascularization, which is mediated by the PI3K/AKT and MEK/ERK signaling pathways (42,44). RGZ has been shown to exert an inhibitory effect on cell proliferation by downregulation of the PI3K/AKT and ERK1/2 signaling pathways (45,46). Our previous study showed that RGZ can suppress IGF-1 or HIF1α expression in RPMI-8226 and primary myeloma cells. Therefore, it was hypothesized that RGZ downregulates IGF-1 or HIF1α expression levels through the PI3K/AKT and ERK signaling pathways. In the present study, when RPMI-8226 cells were cultured with various concentrations of RGZ for 48 h, the expression levels of pAKT and pERK gradually decreased concentration-dependently. At an RGZ concentration of 40 μmol/l, pAKT and pERK protein expression levels were significantly reduced compared with those in the untreated cells. Therefore, RGZ may inhibit IGF-1 or HIF1α expression in a concentration-dependent manner through the PI3K/AKT and ERK signaling pathways.

In conclusion, a previous study has demonstrated that treatment with RGZ can induce growth inhibition in MM cells through cell cycle arrest, cell differentiation and apoptosis. The current study extends the data of previous studies to demonstrate that HIF1α and IGF1 are highly expressed in primary myeloma cells and RPMI-8226 cells, and provides novel evidence that RGZ may inhibit angiogenesis concentration-dependently in RPMI-8226 cells and primary myeloma cells through downregulation of the expression levels of HIF1α and IGF1. Furthermore, the findings of the present study provide additional evidence that RGZ may inhibit IGF-1 or HIF1α expression concentration-dependently through the PI3K/AKT and ERK signaling pathways. Therefore, these findings suggest that the peroxisome proliferator-activated receptor-γ ligand RGZ can be regarded as an angiogenesis inhibitor for the clinical treatment of myeloma and that it constitutes a promising therapeutic approach for patients with MM.

Acknowledgements

This study was supported by grants from the project of the Jiangsu Natural Science Foundation (no. BK2012610), The Colleges and universities Natural Science Fund of Jiangsu Province (no. SZ12306612) and The Social Development Fund of Suzhou City (no. SYS201134). The authors would like to thank all of the patients who provided samples for this study.

References